Therapeutic uses of eicosapentaenoic acid
CA 2052577 C · Owner: Tisdale, Michael John · Inventors: Tisdale, Michael John; Beck, Susan Anne
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The use of the omega-3 polyunsaturated fatty acid eicosapentaenoic acid or EPA, of high purity and preferably substantially free of any other polyunsaturated fatty acids, is disclosed for making up medical preparations or compositions for the treatment of cachexia and/or malignant tumours in mammals. Treatment with EPA is also useful for inhibiting lipolytic activity of biologically active lipolytic agents present in body fluids and the activity of the enzyme, guanidinobenzoatase as well as for reducing abnormal, cAMP levels in cells of adipose tissue in mammals produced by lipolytic or fat mobilising substances.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed October 1, 1991 and granted January 11, 2000. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended October 1, 2011.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by October 1, 2013.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.